AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Sugabit-M 80mg/500mg Tablet

Prescription Icon
Prescription Required

Marketer

Bonsai Pharma

Salt Composition

Gliclazide (80mg) + Metformin (500mg)

Overview Sugabit-M 80mg/500mg Tablet

DiaBeta-Duo 80mg/500mg tablets are classified as antidiabetic medications, combining two active ingredients to manage type 2 diabetes in adults. This medication helps regulate blood glucose levels. DiaBeta-Duo 80mg/500mg tablets should be ingested with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continued use is crucial, even with controlled blood sugar, as discontinuation without medical guidance can elevate blood glucose, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan, encompassing diet, exercise, and weight management as prescribed by your doctor. Lifestyle choices significantly impact diabetes control. Common adverse reactions include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors; constipation; and vomiting. Always carry a fast-acting glucose source (e.g., sugary foods or juice) to counteract hypoglycemia and maintain regular mealtimes. Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Additional possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before commencing treatment. Pregnant or lactating women should consult their doctor. Regular blood glucose monitoring and periodic blood tests (to assess blood cell counts and liver function) are recommended.

Primary Ingredients of Sugabit-M 80mg/500mg Tablet

The provided text is "undefined," which lacks meaning and cannot be rephrased.

Uses of Sugabit-M 80mg/500mg Tablet

Adult-onset diabetes

Major Benefits of Sugabit-M 80mg/500mg Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Administer Sugabit-M 80mg/500mg tablets with a meal.

Common Side effects of Sugabit-M 80mg/500mg Tablet:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Sugabit-M 80mg/500mg Tablet:

Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Sugabit-M 80mg/500mg tablets with food.

How Sugabit-M 80mg/500mg Tablet works:

Gliclazide and metformin, combined as Sugabit-M 80mg/500mg tablets, offer dual-action antidiabetic therapy.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sugabit-M 80mg/500mg tablets with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sugabit-M 80mg/500mg tablets is contraindicated during pregnancy due to confirmed risks to the fetus. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the hazards. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sugabit-M 80mg/500mg tablets while breastfeeding is likely inadvisable. Available evidence from human studies indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if you experience such symptoms.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sugabit-M 80mg/500mg tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Sugabit-M 80mg/500mg tablets. Physician consultation is essential. Regular kidney function monitoring is recommended during treatment.

LiverLiverCAUTION

The use of Sugabit-M 80mg/500mg tablets requires careful consideration in individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised. For patients experiencing mild to moderate liver disease, initiation should be at a reduced dosage; however, its use is contraindicated in those with severe hepatic dysfunction.

What if you forget to take Sugabit-M 80mg/500mg Tablet :

Should you forget a Sugabit-M 80mg/500mg Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sugabit-M 80mg/500mg Tablet

LabelValue
Potential for Dependence None.
Type of Medication Medication for diabetes

FAQs on Sugabit-M 80mg/500mg Tablet

The dual-component tablet, Sugabit-M 80mg/500mg, comprises gliclazide and metformin, and is employed in managing type 2 diabetes mellitus. In adults, it helps regulate blood sugar when combined with a suitable diet and consistent physical activity. Gliclazide functions by stimulating insulin secretion from the pancreas, thereby reducing blood glucose. Metformin acts by decreasing hepatic glucose production and enhancing insulin responsiveness. This medication is unsuitable for treating type 1 diabetes.
Sugabit-M 80mg/500mg tablets may cause frequent side effects such as low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, loose stools, headache, and upper respiratory infections. While uncommon, serious adverse reactions including lactic acidosis are possible. Prolonged use might result in vitamin B12 deficiency.
Indeed, taking Sugabit-M 80mg/500mg tablets may lead to hypoglycemia, characterized by low blood sugar. Manifestations of this condition can encompass nausea, headache, irritability, hunger pangs, sweating, lightheadedness, a rapid pulse, and feelings of anxiety or tremors. The likelihood increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is recommended.
Lactic acidosis, a serious medical condition stemming from excessive blood lactic acid, is a potential side effect of Sugabit-M 80mg/500mg Tablet. Also termed Metformin-associated lactic acidosis (MALA), this complication is infrequent but necessitates immediate medical attention. Its occurrence is minimized by avoiding use in individuals with kidney impairment, the elderly, or those consuming substantial alcohol. Symptoms may manifest as muscle aches or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal discomfort, or bradycardia. Should these symptoms arise, discontinue Sugabit-M 80mg/500mg Tablet and seek prompt medical advice.
Prolonged use of Sugabit-M 80mg/500mg tablets can indeed lead to vitamin B12 deficiency. This is because the medication hinders the stomach's absorption of vitamin B12. Left unaddressed, this deficiency may result in anemia, neurological complications such as tingling and numbness in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and gait instability. To mitigate these risks, supplemental vitamin B12 intake, at least annually, is recommended by some studies.
Patients with hypersensitivity to Sugabit-M 80mg/500mg Tablet constituents or inactive ingredients should not take this medication. Its use is contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Combining Sugabit-M 80mg/500mg tablets and alcohol is unsafe. This combination risks dangerously low blood sugar (hypoglycemia) and heightened lactic acidosis.
The oral medication Sugabit-M, containing 80mg of Gliclazide and 500mg of Metformin, manages type 2 diabetes mellitus in adults. Its efficacy relies on concurrent dietary modification and physical activity to regulate blood sugar. Gliclazide's mechanism involves stimulating pancreatic insulin secretion, while Metformin reduces hepatic glucose output and enhances insulin responsiveness. This dual-agent therapy is unsuitable for type 1 diabetes.
Taking Sugabit-M 80mg/500mg tablets may cause frequent side effects such as low blood sugar, changes in taste perception, queasiness, abdominal discomfort, loose stools, head pain, and upper respiratory illnesses. Rare but potentially severe adverse reactions, including lactic acidosis, are also possible. Prolonged use might result in vitamin B12 insufficiency.
Indeed, taking Sugabit-M 80mg/500mg Tablets may lead to hypoglycemia, characterized by low blood glucose. This can manifest as nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremor. The risk increases with missed or delayed meals, alcohol consumption, strenuous physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Always carry a readily available source of glucose, such as glucose tablets, honey, or fruit juice.
Indeed, Sugabit-M 80mg/500mg Tablet use carries a risk of lactic acidosis, a serious medical condition stemming from excessive blood lactic acid. Also termed MALA (Metformin-associated lactic acidosis), this is an uncommon adverse reaction to metformin. Risk is heightened in individuals with pre-existing kidney impairment, the elderly, or those consuming substantial alcohol. Lactic acidosis symptoms can manifest as muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, nausea, vomiting, abdominal discomfort, or a slowed pulse. Should these symptoms appear, discontinue Sugabit-M 80mg/500mg Tablet intake and seek immediate medical attention.
Indeed, prolonged use of Sugabit-M 80mg/500mg tablets can lead to vitamin B12 deficiency. This deficiency arises from the medication's interference with gastric vitamin B12 absorption. Left unaddressed, this can manifest as anemia, neurological complications including paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive changes, and gait instability. To mitigate these risks, supplemental vitamin B12 intake, at least annually, has been proposed by some investigators.
Patients with a documented hypersensitivity to Sugabit-M 80mg/500mg Tablet constituents or inactive ingredients should not receive this medication. Its administration is also contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Combining Sugabit-M 80mg/500mg tablets with alcohol is unsafe. This combination can exacerbate hypoglycemia and heighten the risk of lactic acidosis.
Sugabit-M 80mg/500mg Tabl...
41
MRP 50
18% off